Gastrointestinal

Pancreatic Tumors

Treatment

Non-resectable

Metastatic

GI0027
Brightline-2: Phase IIa/IIb B1 907828 in Locally Advanced / Metastatic, MDM2 Amplified TP53 Wild-Type Biliary Tract Adenocarcinoma Pancreatic Ductal Adenocarcinoma or Other Selected Solid Tumours

PI: Chen Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.

PANC0038
PIC10044: Immunotherapy Platform Trial for Metastatic Pancreatic Adenocarcinoma

PI: Fisher Sponsor: Stanford University

GI0025
Phase I Study to Evaluate Safety Tolerability Pharmacokinetics & Preliminary Anti-tumor Activity of PEEL-224 in Advanced Solid Tumors

PI: Fisher Sponsor: PEEL Therapeutics, Inc.

ECOG-ACRIN-A021806
Phase III Perioperative vs Adjuvant Chemotherapy in Resectable Pancreatic Cancer

PI: Poulsides Sponsor: ECOG-ACRIN

KEY

Pending
Open for Enrollment
Optional Path
Trial Posting
Extension Study
Immunotherapy
Observational Study
Enrollment on Hold

Version Date: May 9, 2023.